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Proteases, Cathepsin S, Angiogenesis, Tumourigenesis, Stroma.  
 
Novelty and Impact  
 
Cathepsin S is a protease that is upregulated in multiple tumour types. Using 
a syngeneic murine model, we were able to evaluate the contribution of 
cathepsin S from both tumour and tumour-associated cells, clearly showing 
for the first time that both sources can contribute this protease to promote 
tumourigenesis. These results reveal a mechanism by which tumour and 
recruited cells cooperate in tumour development and validate cathepsin S as 
an anti-angiogenic and anti-proliferative drug target.  
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Recent murine studies have demonstrated that tumour-associated 
macrophages in the tumour microenvironment are a key source of the pro-
tumourigenic cysteine protease, cathepsin S. We now show in a syngeneic 
colorectal carcinoma murine model that both tumour and tumour-associated 
cells contribute cathepsin S to promote neovascularisation and tumour growth. 
Cathepsin S depleted and control colorectal MC38 tumour cell lines were 
propagated in both wild type C57Bl/6 and cathepsin S null mice to provide 
stratified depletion of the protease from either the tumour, tumour-associated 
host cells, or both. Parallel analysis of these conditions showed that deletion 
of cathepsin S inhibited tumour growth and development, and revealed a clear 
contribution of both tumour and tumour-associated cell derived cathepsin S.  
The most significant impact on tumour development was obtained when the 
protease was depleted from both sources. Further characterisation revealed 
that the loss of cathepsin S led to impaired tumour vascularisation, which was 
complemented by a reduction in proliferation and increased apoptosis, 
consistent with reduced tumour growth. Analysis of cell types showed that in 
addition to the tumour cells, tumour-associated macrophages and endothelial 
cells can produce cathepsin S within the microenvironment. Taken together, 
these findings clearly highlight a manner by which tumour-associated cells 
can positively contribute to developing tumours and highlight cathepsin S as a 
therapeutic target in cancer. 
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Cathepsin S (CatS) is a cysteine protease, found abundantly in antigen 
presenting cells (APCs), where it is known to have key roles in MHC class II 
antigen processing and presentation.1,2 This potent elastinolytic and 
collagenolytic enzyme is unique amongst the 11 human lysosomal cysteine 
cathepsins due to its ability to retain its activity in more neutral pH conditions, 
such as the extracellular environment.3,4 Consequently, CatS has been 
implicated in a number of disease states, where it is secreted and promotes 
the remodelling of extracellular matrix (ECM) components, especially in 
conditions such as rheumatoid arthritis, atherosclerosis and cancer.5-10 
 
Clinically, the up-regulation of CatS in tumours has been observed in prostate, 
gastric, colorectal and brain tumours.11-14 Indeed, in astrocytomas, increased 
CatS levels correlate with advancing tumour grade and a poorer patient 
prognosis.15,16 In addition, we have recently observed similar prognostic value 
in colorectal cancer (CRC), detecting marked up-regulation in all tumour 
stages.13,17  
 
Further insight into the role(s) of CatS in tumour development has been 
provided using murine tumour models. CatS null (CatS-/-) mice crossed with 
the spontaneous pancreatic beta cell carcinogenesis model (RIP1-Tag2) 
established that CatS can promote tumourigenesis through increased 
invasiveness, activation of angiogenesis and tumour neo-vascularisation.10,18 
It highlighted that a major source of CatS in these tumours was infiltrating 
tumour-associated macrophages (TAMs).19 However, our previous analyses 
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of human tumour cell lines and clinical biopsies from brain and colorectal 
carcinomas demonstrated that tumour cells also produce significant levels of 
this protease.13-17,20 Therefore, in this current investigation, we wished to 
further evaluate the role and the cellular contribution of CatS in a syngeneic 
immuno-competent CRC tumour model, comparing both C57Bl/6 wild type 
(WT) and CatS-/- mice. These studies show a clear contribution of CatS from 
both tumour and tumour-associated cells, which promote angiogenesis and 
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Materials and Methods 
 
Cell lines 
MC38 colon adenocarcinoma cells (S Rosenberg, NCI), B16-F10 murine 
melanoma cells (ATCC) and RAW 264.7 leukaemic monocyte macrophage 
cells (ATCC) were routinely cultured in DMEM (Invitrogen, UK) supplemented 
with 10% FBS (PAA, UK), 100 µg/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen, UK). The Lewis lung carcinoma line (LLC) (ATCC) was similarly 
cultured in RPMI 1640 (Invitrogen, UK).  
 
Immunofluorescent staining 
Paraformaldehyde-fixed cells were stained overnight using goat anti-CatS or 
non-immune goat primary antibodies  (R & D Systems, UK) (15 µg/ml) and 
secondary Alexa Fluor 488 rabbit anti-goat antibody (Molecular Probes, UK) 
(4 µg/ml, 30 min). Cells were rinsed and mounted with Vectashield with 4',6-
diamidino-2-phenylindole (DAPI) (Vectorlabs, UK) counterstain, and 
visualized on the Leica TCS SP5 DMI6000 CS confocal microscope with 
Leica LAS AF software. 
 
Reverse transcriptase-PCR 
Detection and amplification of mRNA from STAT60 purified total RNA 
(Biogenesis, UK) for CatS and GAPDH was performed using the ImProm-II 
Reverse Transcriptase system (Promega, UK) following manufacturer’s 
instructions. The following primers were used at an annealing temperature of 
53 °C for 35 cycles: CatS (5’ ATGAAACGGCTGGTTTGTGTGC ’3, and 3’ 
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CTAGATTTCTGGGTAAGAGGG ’5) and GAPDH (5’ 
ACCACAGTCCATGCCATCAC ’3 and 3’TCCACCACCCTGTTGCTGTA’5). 
The PCR products were visualized by agarose gel electrophoresis on a 1% 
gel. 
 
Retroviral transfection and transductions 
Murine CatS-specific short-hairpin RNAs (shRNA) and control constructs in 
pGFP-V-RS (10 µg) (OriGene Technologies) were transfected with packaging 
vector pCL-ECO (3.3 µg) into PlatE cells (Invitrogen, UK) using Lipofectamine 
2000 (Invitrogen, UK). After 72 h, 1 ml viral supernatants were collected, 
filtered through a 0.45 µm filter and mixed with 1 ml of fully supplemented 
DMEM containing 6 µg/ml PolyBrene (Sigma, UK) and added to MC38 cells 
(2 x 105). 24 hr post-infection, medium was replenished and stable cells 
selected in puromycin (10 µg/ml) for a minimum of 14 days. 
 
Cellular Characterisation Assays 
Invasion assays were performed as previously described using the CatS 
inhibitory antibody, Fsn0503 (Fusion Antibodies, UK).13 Ten representative 
field of view images were taken from duplicate membranes using the Nikon 
DXM1200 digital camera (X 20 objective lens). Results were analysed using 
Lucia GF 4.60 laboratory imaging and data presented as percentage mean 
number of invaded cells per field of view ± SEM.  Live cell proteolysis assays 
were performed with 1 X 105 MC38 Sc and MC38 S4 cells seeded on cover 
slips coated in DQ-gelatin (Molecular Probes, UK) supplemented Matrigel (BD 
Biosciences, UK) and were visualized on the Leica TCS SP5 DMI6000 CS 
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confocal microscope with Leica LAS AF software.13 CatS-like activity and pan-
MMP activity was determined by fluorimetric assay as previously described 
using Cbz-Val-Val-Arg-aminomethylcoumarin 20 (Calbiochem, UK) and 520 
MMP FRET substrate XIV (AnaSpec, USA), respectively. 
 
In vivo experiments 
All mice used in experiments were between 8 – 12 weeks of age with housing 
and experimentation carried out in accordance with the Animal (Scientific 
Procedures) Act 1986, the current UKCCCR guidelines and approved by the 
Queen’s University Ethical Review Committee. C57Bl/6 mice were purchased 
from Charles Rivers Laboratories and also bred in-house. CatS-/- mice were 
obtained from J. A. Joyce, Memorial Sloan Ketting Cancer Center, New York 
with permission from H Chapman, UCSF. The mice were subcutaneously 
injected with 5 x 105 MC38 or B16-F10 cells mixed with reduced growth factor 
Matrigel to a final concentration of 4 mg/ml (BD Biosciences). Tumour 
volumes were calculated with digital callipers, using the formula, V = a X b2 X 
π/6, where a and b represent the longer and shorter diameter of the tumour, 
respectively. Data was presented as mean tumour burden (mm3) per group ± 
SEM. 
 
Assessment of vessel functionality 
Fluorescein-labelled lectin (Lycopersicon esculentum) (Sigma, UK) was 
injected into the tail vein (1 mg/ml, 100 µl/mouse) and allowed to circulate for 
5 min prior to heart perfusion with 10% formalin for 5 min. Tumours were 
excised, embedded in optimal cutting temperature (OCT) compound and 
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sectioned at 10 µm thickness before mounting with Vectashield containing 
DAPI (Vectorlabs, UK). Tumour vessel permeability was assessed via Evan’s 
blue perfusion for 60 min (tail vein injection, 20 mg/ml, 100 µl/mouse), prior to 
formalin fixation. Evan’s blue content of excised, dried tumours was 
determined after formamide extraction at 620 nm. 
 
Immunohistochemistry of tumour samples and analysis 
Tumour sections were formalin fixed, paraffin-embedded and subjected to 
immuno-staining as previously described.13 Antibodies and concentrations 
used were as follows; rat anti-mouse CD34 (1:50) (Abcam), rabbit anti-human 
Ki67 (1:300) (Abcam), rat anti-mouse CD45 (1:100) (BD Biosciences, UK), rat 
anti-mouse CD68 (1:50) (Biolegend, UK) and anti-human CatS (1:200) (R&D 
Systems).    
 
Mean vessel number (MVN) and vessel area was determined by CD34 
staining. A minimum of ten random fields of view per tumour were taken under 
X 20 and X 40 objective lens (Leica DM5500B microscope and AL software). 
CD34 positive blood vessels and vessel area were calculated and expressed 
as the MVN ± SEM and mean area (µm2) ± SEM, respectively. The 
percentage of Ki67 positive cells was determined by the selection of four 
random fields of view per tumour, in each group under X 40 objective lens. 
Both total cell numbers and Ki67 positive cells were determined and the data 
presented as mean Ki67 positive cells (%) ± SEM.    
 
In Situ Detection of Apoptosis by TUNEL Staining 
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Paraffin-embedded tumour sections were stained for apoptotic cells using 
terminal deoxynucleotidyl transferase-mediated dUDP-nick-end labelling 
(TUNEL)-based TumorTACS™ In Situ Apoptosis Detection Kit (R&D Systems, 
UK) as per the manufacturer’s instructions. TUNEL staining was assessed by 
the random selection of five fields of view per tumour, in each group under X 
20 objective lens. The number of TUNEL positive cells were counted and 
presented as total mean TUNEL positive cells per field of view (Mean ± SEM).  
 
Flow cytometry 
Tumours were disaggregated and digested in 0.125% trypsin for 20 min at 
37 °C, with agitation. DMEM media (2% FCS) was added to the cell 
suspension and filtered through a nylon mesh (BD Biosciences, UK) to 
remove debris. The cell suspension was washed, centrifuged at 1000 g and 
resuspended in sterile PBS to a density of 1 X 106 cells/ml. To reduce 
nonspecific binding, cells were blocked on ice for 10 min using Mouse BD Fc 
block (BD Biosciences, UK). Cells were then stained, in the dark, on ice for 30 
min with optimal antibody concentrations, which was determined by titration 
experiments. Antibodies used included anti-mouse F4/80 conjugated to PE-
Cy7 (EBioscience, UK), anti-human CatS (R&D Systems, UK) conjugated with 
PE-Cy5 lightning link (Biolegend, UK) as per manufacturer's instructions and 
anti-mouse CD11b conjugated to APC (BD Biosciences, UK). Flow cytometry 
was performed with a BD FacsAria II with FacsDiva software and data 
analysis was performed using Flowjo.  
 
Statistical analysis.  
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For the analysis of tumour growth, tumour vessel number, tumour vessel area, 
proliferation rate and apoptosis, the mean and SEM was established from all 
tumours in each group investigated. The statistical analyses were performed 




CatS is expressed in murine tumour cell lines 
In this current investigation, an immuno-competent tumour model was used to 
study the contribution of CatS from both the tumour and tumour-associated 
cells, reflecting the distribution of the protease that has been observed 
clinically.15-17 MC38 colorectal adenocarcinoma, B16-F10 melanoma and 
Lewis lung carcinoma (LLC) cell lines were selected (syngeneic with C57Bl/6 
backgrounds) and examined to determine the level of CatS expression. RAW 
264.7 macrophage-like cells were used as a positive control and CatS mRNA 
levels were positively detected in all lines by RT-PCR (Figure 1A). 
Immunofluorescent microscopy was then used to detect the presence of CatS 
protein in each of the tumour cell lines using RAW 264.7 cells as a positive 
control.  As anticipated, the RAW 264.7 cells revealed the highest levels of 
CatS staining, whilst in the tumour lines, MC38 cells produced the most 
intense staining (Figure 1B). Enhancement of the fluorescence signal in the 
MC38 cells clearly showed punctate vesicular localisation of the protease, 
consistent with our previous findings in tumour cells13 (Supplementary Figure 
S1). Western blotting was also used to analyse the levels of CatS, but this 
proved inconclusive due to high background levels (data not shown).  
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Previously, we have shown that in human tumour lines, secreted CatS can 
promote invasion, which could be blocked with a CatS specific antibody-
based inhibitor, Fsn0503.13 Here, we were able to confirm that Fsn0503 
similarly inhibited MC38 cell invasion in a dose dependent manner (p = 0.002 
at 500 nM)  (Figure 1C). Taken together, these data demonstrate expression 
of CatS by MC38 cells, which promotes their invasive potential in a manner 
akin to what we have previously observed in human tumour cell lines.13  
 
Gene silencing of CatS in MC38 cells reduces tumour cell invasive 
potential  
The establishment of CatS-depleted MC38 cell lines was undertaken using 
retroviral shRNA constructs specific for murine CatS in parallel with a 
scrambled control. The knockdown of CatS was initially analysed by RT-PCR, 
where CatS-specific shRNA constructs 3 (S3) and 4 (S4) yielded the most 
efficient knockdown in CatS mRNA levels (Figure 2A). The effect of CatS 
knockdown clearly reduced the invasive nature of the transduced cells with 
the most significant reduction observed in the MC38 S4 cells (62%, p = 
0.0001) (Figure 2B, experiments carried out at least 3 times). This inhibition is 
more pronounced than in Figure 1C which is as expected as the antibody-
based inhibitor used in Figure 1C will only target extracellular CatS as 
opposed to the shRNA which diminishes total protein. Immunofluorescent 
staining for CatS protein was also carried out on the transduced lines, where 
a marked reduction in CatS protein levels was observed in the MC38 S4 cells 
compared to the control Sc cells (representative images of MC38 Sc versus 
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S4 cells shown in Figure 2C). The MC38 S4 cells were also examined for 
CatS-like activity, revealing a 59% reduction when compared to both the 
MC38 Sc cells and un-transfected MC38 cells (Figure 2D).  
 
A live-cell proteolysis assay was undertaken to compare the MC38 S4 and Sc 
cells in the presence of DQ-gelatin, which upon degradation emits a bright 
green fluorescence. The degradation of this substrate in the pericellular 
environment was noticeably blunted by depletion of CatS (Figure 2E), which is 
in agreement with effects we previously observed in human cell lines with 
Fsn0503.13 It is possible that the marked difference we observed was due to 
alterations in secreted MMP activity, such as MMP2 and MMP9, induced by 
the deletion of CatS. To address this, supernatants from the cell lines were 
analysed in a fluorimetric activity assay using a pan-MMP internally quenched 
substrate, but little difference was observed (Supplementary Figure S2).  
Finally, prior to in vivo experimentation, alterations in the proliferation rate of 
the MC38 S4 cells when compared to the MC38 Sc control cells was also 
examined with no discernable differences observed (Supplementary Figure 
S3).  
 
Depletion of host and tumour-derived CatS attenuates tumour 
development 
In order to first evaluate the contribution of CatS from host cell-derived CatS 
in the syngeneic model, parental MC38 cells were injected into both C57Bl/6 
WT and CatS-/- mice. Daily tumour measurements clearly showed that 
progression of these tumours was significantly attenuated in the CatS-/- mice 
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with a 52% reduction (p = 0.023) in tumour burden observed after 16 days 
when compared to the tumours from the WT mice (Figure 3A). To confirm that 
these effects were not specific to MC38 cells, a similar study was performed 
using B16-F10 cells. Again, a significant reduction in tumour growth was 
apparent in the tumours from the CatS-/- mice with a 55% (p = 0.015) 
reduction in tumour burden observed after 14 days (Figure 3B).  
 
With the importance of host cell-derived CatS in tumour progression 
established, the contribution of the protease from the tumour cells was then 
evaluated. The CatS-depleted MC38 S4 and scrambled control Sc cells were 
propagated in both CatS-/- and WT mice. In the initial stages of the study, it 
appeared that the absence of host CatS was the predominant factor in 
comparison to tumour-derived CatS, given that by day 10, depletion of the 
tumour-derived protease had no discernable effect (Figure 3C). However, 
after 15 days it was apparent that depletion of CatS from either the tumour 
cells or the microenvironment similarly attenuated tumour development 
(Figure 3C).  Nonetheless, the most pronounced effect was observed when 
CatS was ablated from both tumour and tumour associated cells (65.7% 
reduction, p = 0.0016).  
 
Tumour vascularisation and tumour vessel functionality is reduced in 
CatS-depleted tumour microenvironment 
Following completion of in vivo studies, tumours were initially analysed by 
general histological analysis, revealing a robust tumour type with clear 
vascularisation and little evidence of necrosis (representative images shown 
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in Supplementary figure S4). To examine the neovascularisation in more 
detail, immunohistochemical staining for the endothelial marker, CD34, was 
performed. This clearly distinguished the neovasculature in the tumours, as 
highlighted with arrows in Figure 4A. Quantitative analysis of CD34-positive 
mean vessel number (MVN) from the tumour sections revealed that when 
CatS was deleted from both the tumour and tumour-associated cells, a 
significant reduction in MVN was observed (p = 0.0001) (Figure 4B). The 
mean vessel area was also measured in these sections showing that CatS 
depletion from either source resulted in a significant reduction in vessel area. 
However as before, the most pronounced effects were observed when the 
protease was removed from all cell types (p = 0.0001) (Figure 4C).  
 
Further qualitative evidence that the tumour vasculature was affected by CatS 
depletion was provided through perfusion of FITC-labelled lectin to identify 
functional vasculature. This indicated that the vessels appeared more poorly 
defined in the tumours that lacked CatS from both tumour and tumour-
associated cells (Supplementary figure S5). Moreover, the depletion of CatS 
from either source clearly promoted leakiness of the neovasculature as 
determined by Evan’s blue perfusion, with the most marked effects observed 
in tumours lacking the protease from both sources (p = 0.0289) (Figure 4D). 
Given the pronounced effects observed on tumour angiogenesis, tumour 
lysates from the tumour and host CatS positive (WT with Sc cells) versus the 
tumour and host CatS negative (-/- with the S4 cells) arms were analysed for 
several angiogenic factors to determine if they were altered by depletion of 
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CatS where it was found that both acidic and basic FGF levels were increased 
(Figure 4E). 
 
CatS depletion results in reduced proliferation and increased apoptosis 
in tumours 
On the basis of the effects observed on tumour neovascularisation, we next 
examined the tumours for possible alterations in proliferation and apoptosis 
via Ki67 and TUNEL staining, respectively.  The MC38 tumours from all four 
arms of the investigation stained intensely for Ki67. When CatS was depleted 
from either the tumour cells or host cells alone, no significant reduction in 
tumour cell proliferation was apparent (Figure 5A and 5B). However, when 
CatS was depleted from both sources, a significant reduction in proliferation 
was clearly observed (17% reduction, p = 0.0017) (Figure 5B).  
 
Furthermore, we also examined the tumour sections for apoptosis by TUNEL 
staining and as highlighted by arrows in Figure 5C, it was found that the 
decrease in proliferation was complimented by an increase in apoptosis, 
again most significantly when CatS was depleted from both tumour and 
tumour associated cells (p = 0.0012) (Figure 5D).  
 
Tumour, macrophage and endothelial cells contribute CatS to the 
tumour microenvironment  
Finally, we wished to further clarify the different cellular contributors of CatS to 
the microenvironment in these MC38 tumours. Immunohistochemical 
detection of CatS from the tumours using the MC38 Sc line in the WT animals 
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clearly showed diffuse positive staining for the protease, which was 
decreased as expected in tumour sections from each of the CatS-depleted 
arms, most noticeably in depleted host and tumour (Figure 6A). Upon closer 
examination of these stained sections, it was revealed that the MC38 Sc 
tumours in WT mice demonstrated intense CatS positivity in the tumour 
endothelium compared to the MC38 S4 cells in the CatS-/- mice as highlighted 
by arrows in Figure 6B i & ii. 
 
Determination of macrophage-derived CatS contribution was undertaken by 
FACS. Tumours were excised and pooled to generate single cell suspensions 
and tumour-associated macrophages were selected using F4/80 and CD11b 
markers and further assessed for CatS positivity. The scatter plot revealed a 
population of CD11b+/F4/80+ cells (4.8%), which demonstrated varying levels 
of CatS positivity (Figure 6C). A similar finding of macrophages with varying 





In this current study, we aimed to bridge the gap between clinical 
observations and prior murine studies, whereby the contribution of CatS from 
both tumour cells and recruited host cells within the tumour microenvironment 
was examined. Upon validation of the expression and functionality of CatS in 
the colorectal carcinoma cell line MC38, we conducted in vivo studies with 
paired scrambled and CatS-depleted MC38 cell lines in wild-type and CatS-/- 
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animals. We showed that the ablation of CatS had a considerable impact on 
tumour development and progression; most significantly when CatS was 
depleted both from tumour (via shRNA knockdown) and tumour-associated 
cells (via CatS-/- host background). These results mirror the combinative 
effects of tumour and stroma-derived contribution of cathepsin B which has 
previously been observed in the MMTV-(PyMT) mammary tumour model.22 
 
Cysteine cathepsins have previously been implicated in tumourigenesis, 
facilitating various tumour-associated processes such as invasion, metastasis 
and angiogenesis.8,23 However, amongst these proteases, CatS has unique 
properties in that it is stable at neutral pH and is a potent elastase and 
collagenase.24 Furthermore, it has been suggested to have more 
physiological importance than other cysteine cathepsins in processing 
proteins in the extracellular microenvironment.25 Indeed, given that CatS has 
been shown to promote the activation of other cysteine cathepsins and 
normally demonstrates restricted expression largely confined to APCs,1,25 it 
may represent a more pertinent therapeutic target than other family members 
in cancer.   
 
The de-regulated expression of CatS has been identified in a range of human 
tumour types including lung, brain, colorectal and prostate carcinomas.11-17, 26 
It is known that CatS can be up-regulated by a number of tumour-associated 
angiogenic factors such as VEGF and bFGF,20,27 but mechanisms 
underpinning this remain poorly defined and clearly warrant research in the 
future.  
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Interestingly, recent analysis of over 3100 tumour specimens across 26 
cancers, established that chromosome region 1q21.2 where the CatS gene is 
located is frequently somatically amplified. This is a consequence of the 
addiction of tumours to the anti-apoptotic gene Mcl-1 found at this locus, and 
therefore, it is possible that the up-regulation of CatS may be a collateral 
effect of tumours adopting this anti-apoptotic phenotype.28  
 
In this current study, the major effect caused by the stratified deletion of CatS 
clearly highlighted deficiencies in developing tumour neovasculature. The 
analyses revealed that loss of CatS reduced the mean vessel number and 
area and resulted in impaired functionality of the tumour vasculature. These 
effects are in agreement with previous studies that have highlighted a clear 
pro-angiogenic role for CatS in tumour development.10,13,18,19 The impact of 
impaired tumour vascularization and integrity was complemented with a clear 
reduction in proliferation and increased apoptosis in these tumours.  This is in 
agreement with the observations of Wang et al. using the RIP1-Tag2 model.18 
Interesting, another study using the same RIP1-Tag2 model observed no 
alterations in proliferation with CatS deletion, which may be attributed to 
differences in study design or assays employed.10  Given that no effect was 
observed on the proliferation rate of the transfected MC38 cells in vitro, the 
noted reduction in vivo may be attributed to defective tumour vascularisation. 
Furthermore, Wang et al, reported an increase in tumour FGF concentrations 
induced by the deletion of CatS, which was similarly observed in our studies. 
This suggests that the CatS-depleted tumours may have activated alternative 
pro-angiogenic mechanisms in order to overcome the impediment on 
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neovascularization caused by the lack of CatS, which has been observed 
previously with other anti-angiogenic compounds.29,30  An additional finding 
noted in this present model was that vessel leakiness within the tumours was 
increased in the absence of CatS. This could be a consequence of improper 
ECM and/or endothelial cell-to-cell junction proteolytic processing, mediated 
by CatS. This suggests that CatS may have more intricate roles in controlling 
neoangiogenesis. Indeed, a recent investigation into post-translational 
modification of endostatin showed that CatS may also have anti-angiogenic 
roles,31 highlighting that this protease may indeed mediate both pro- and anti-
angiogenic effects to promote coordinated neovascularization.  
 
In addition to the production of CatS by the tumour cells, further analysis of 
microenvironmental contributors confirmed that TAMs produced the protease 
as previously shown in the RIP1-Tag2, MMTV-Pymt and 4T1 tumour models. 
10,19,21,34 Here, we also found that endothelial cells were CatS positive, 
confirming CatS up-regulation previously detected at the mRNA level in 
murine tumour-associated endothelium.32  
 
In conclusion, these studies have clearly shown that CatS can be contributed 
to the tumour microenvironment by both tumour cells and tumour-associated 
cells in this syngeneic model. These studies also show a mechanism by which 
tumour-associated cells promote tumour neoangiogenesis and proliferation, 
and further validates CatS as a therapeutic target.  These results are 
particularly relevant given the recent finding that CatS can be up-regulated33 
by front-line chemotherapies may also contribute to chemotherapy 
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resistance.34 Furthermore, this model provides a useful platform for the 
evaluation of CatS inhibitors in future studies.  
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Figure 1. Characterization of CatS expression in syngeneic tumour cell 
lines. (A) LLC, MC38, B16-F10 tumour cells and RAW 264.7 monocytic cells 
were analyzed by RT-PCR for CatS at the mRNA level, revealing the 
presence of mRNA in all cell lines. GAPDH was used as a loading control. (B) 
Representative images demonstrated CatS expression in these cells lines by 
the immuno-fluorescent staining of CatS and counterstained with DAPI. X 40 
objective lens. Scale bar = 25 µm & 50 µm. (C) Invasion assay performed with 
Fsn0503 antibody inhibited the invasion of MC38 cells through the matrigel in 
a modified Boyden chamber invasion assay (38% at 500nM). Isotype control 
used at 750nM n=3, Error bars, SEM. ** p = 0.002.  
 
Figure 2. Depletion of CatS decreases invasive potential of MC38 cell 
line. (A) RT-PCR analysis of CatS at the RNA level in MC38 cells upon 
retroviral transfection and transductions with the murine CatS-specific shRNA 
constructs and scrambled control shRNA under puromycin selection. The RT-
PCR data highlighted substantial knockdown with constructs 3 (S3) and 4 
(S4). GAPDH was used as a loading control. (B) Invasion assay 
demonstrated a reduction in the invasive potential of MC38 cells retrovirally 
transduced with S3 and S4 constructs when compared to both scrambled 
control (Sc) and untreated MC38 cells, were a 62% reduction in invasion was 
noted with the MC38 S4 cells when compared to the MC38 Sc cells. Error 
bars, SEM. **** p = 0.0001, *** p = 0.0008, n=3. (C) Representative images of 
the immunofluorescent staining for CatS in the MC38 S4 cells revealed a 
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reduced level of expression when compared to the MC38 Sc cells. Cells 
counterstained with DAPI. X 40 objective lens. (D) Cell lysates (100 µg) were 
analysed for CatS-like activity and the MC38 S4 cells were found to 
demonstrate a reduction in CatS-like activity over controls. Error bars (SEM) 
not visible in MC38 or S4 traces due to minor differences in replicates. (E) 
Cell-based proteolysis assay with MC38 S4 and Sc cells demonstrated a 
reduction in pericellular fluorescence in the MC38 S4 cells when compared to 
MC38 Sc cells. X 40 objective lens. Scale bar = 50 µm. 
 
Figure 3. Ablation of CatS attenuates tumour growth and development in 
vivo. (A & B).  MC38 cells (A) and B16-F10 cells (B) were subcutaneously 
injected into male C57Bl/6 and CatS-/- mice and tumours were measured daily 
with digital calipers. Data are mean tumour volume (mm3) ± SEM (n=12 per 
group) * p = 0.023 for MC38 tumours and * p = 0.015 for B16-F10 tumours. 
(C) MC38 S4 and Sc cells were subcutaneously injected into both C57Bl/6 
(WT) and CatS-/- mice. Tumour measurements were taken as previously 
indicated. Data are mean tumour volume (mm3) ± SEM (n=10 per group). 
Error bars, SEM. * p = 0.016,  ** p = 0.001.   
 
Figure 4. Depletion of host and tumour-derived CatS diminishes tumour-
associated neovascularisation. (A) Representative images demonstrating 
the immunohistochemical staining for CD34 to visualize and quantify tumour 
vasculature within the tumours from each group. Arrows highlight the CD34 
positive tumour vessels in each group. X 20 objective lens. Scale bar = 100 
µm. (B) Quantitative analysis demonstrated that the loss of functional tumour 
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and host CatS from the tumours produced a significant reduction in the mean 
vessel number (MVN) in the MC38 S4 tumours in the CatS-/- mice when 
compared to the MC38 Sc tumours in the WT mice. Data shown as MVN from 
ten tumours in each group, with ten fields of view per tumour assessed. Error 
bars, SEM. **** p = 0.0001. (C) Mean vessel area was also significantly 
reduced in all the groups when compared to the MC38 Sc tumours from the 
WT mice with the most significant effect observed in the MC38 S4 tumours in 
the CatS-/- mice. Data shown as mean vessel area from ten tumours in each 
group. Error bars, SEM. * p = 0.0214, *** p = 0.0008, **** p = 0.0001. (D) The 
depletion of functional tumour and host CatS demonstrated a significant 
increase in tumour vessel leakiness when compared to MC38 Sc tumours in 
the WT mice tumours as measured by Evans blue dye perfusion. Data shown 
as µg Evans blue dye per mg of pooled tumour tissue. Error bars, SEM. * p = 
0.0289. n=3. Statistical analysis performed using the Student t-test. (E) MC38 
Sc tumours from the WT mice and MC38 S4 tumours from the CatS-/- mice 
were pooled, lysed and assessed for both acidic and basic fibroblast growth 
factor (FGF). Almost a 2-fold increase in acidic FGF and 1.5-fold increase in 
basic FGF was noted in the MC38 S4 tumours from the CatS-/- mice when 
compared to the MC38 Sc tumours from the WT mice. Error bars, SEM. 
 
Figure 5. Loss of host and tumour-derived CatS decreases tumour 
proliferation and increases apoptosis (A) Representative images of 
immunohistochemical staining for tumour cell proliferation using the 
proliferative marker, Ki67, in each tumour from each group. X 40 objective 
lens. Scale bar = 100 µm. (B) Quantification of Ki67 positivity revealed 
Page 24 of 41
John Wiley & Sons, Inc.
International Journal of Cancer
 25
decrease in proliferation due to the loss of CatS. Typically, four fields of view 
per tumour were assessed. Data shown as mean Ki67 positive cells (%) 
assessed from ten tumours in each group. Error bars, SEM. ** p = 0.0017. (C) 
Representative images of immunohistochemical staining for tumour apoptosis 
(as highlighted with arrows) using TUNEL staining in each tumour from each 
group. X 20 objective lens. Scale bar = 100 µm. (D) Quantification of TUNEL 
staining revealed increase in levels of apoptosis through the loss of CatS. 
Typically, five fields of view per tumour were assessed. Data shown as mean 
apoptotic cell number assessed from ten tumours in each group. Error bars, 
SEM. ** p = 0.0012.  Statistical analysis performed using the Student t-test. 
 
Figure 6. Cellular contributors of CatS in the MC38 tumour 
microenvironment. (A) Representative images of immunohistochemical 
staining for CatS in the tumours from each group. X 40 objective lens. Scale 
bar = 100 µm. (B(i) and (ii)) Further immunohistochemical analysis 
demonstrated that CatS positivity noted in these tumours was also attributed 
to the endothelium (highlighted by arrows) in the tumour vasculature which 
was also found to be CatS positive (i) when compared to tumours which 
lacked CatS (ii). X 40 objective lens. Scale bar = 100 µm. (C) FACS analysis 
of pooled MC38 Sc tumours from the WT mice revealed that F4/80+/CD11b+ 
population of macrophages. Further characterization of this F4/80+/CD11b+ 
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FIGURE 3 
Arm comparisons % Tumour reduction (p value) 
WT with Sc versus -/- with Sc 38.4% (p = 0.016) * 
WT with Sc versus WT with S4 32.7% (p = 0.436) ns 
WT with Sc versus -/- with S4 65.7% (p = 0.001) ** 
WT with S4 versus -/- with S4  49.1% (p = 0.006) ** 
C 
John Wiley & Sons, Inc.
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Supplementary figure S1 
Confocal micrograph of MC38 cells showing punctate vesicular staining of 
CatS. Fluorescence intensity increased after data acquisition using Leica 
Microsystems LAS AF suite software. X 40 objective lens. Scale bar = 50 µm. 
 
Supplementary figure S2 
Tumour cell conditioned media (50 ȝg) from the MC38 Sc and MC38 S4 cells 
were analysed for pan-MMP extracellular activity.  No apparent alteration in 
activity between the MC38 S4 cells and control MC38 Sc cells was observed. 
Assays were repeated in duplicate with the resultant activity displayed as 
specific activity (RFU min-1 ug-1). Error bars, SEM.  
 
Supplementary figure S3 
MC38 S4 and MC38 Sc cells (1x104) were seeded into 6-well plates and cells 
counts performed every 24 hrs. It was noted that no difference in the 
proliferative rate between the two cell types existed at any time point. Error 
bars, SEM.  Data representative of at least three individual experiments. 
 
Supplementary figure S4 
Representative images of H&E staining of the tumour sections from each arm 
of the in vivo study. X 20 objective lens. Scale bar = 100 µm.  
 
Supplementary figure S5 
Representative images of the tumour vasculature perfused with FITC-labelled 
lectin. Tumour sections were counter-stained with DAPI and imaged by 
confocal microscopy. X 20 objective lens. Scale bar = 50 µm.  
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